| 摘要 |
The present invention provides: a therapeutic agent for diabetes, particularly a therapeutic agent for diabetes which can inhibit the activation of PKCα to thereby exhibit a GLUT4 endocytosis inhibitory activity, said therapeutic agent containing 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as an active ingredient; and others. |
